Research Analysts’ Weekly Ratings Changes for Phreesia (PHR)

A number of firms have modified their ratings and price targets on shares of Phreesia (NYSE: PHR) recently:

• 5/29/2026 – Phreesia had its “market perform” rating reaffirmed by Citigroup Inc..
• 5/28/2026 – Phreesia had its price target raised by Truist Financial Corporation from $11.00 to $12.00. They now have a “hold” rating on the stock.
• 5/28/2026 – Phreesia had its price target lowered by Canaccord Genuity Group Inc. from $22.00 to $16.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Phreesia had its price target raised by Citigroup Inc. from $10.00 to $12.00. They now have a “neutral” rating on the stock.
• 5/28/2026 – Phreesia was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $12.00 price target on the stock.
• 5/28/2026 – Phreesia had its “buy” rating reaffirmed by DA Davidson. They now have a $14.00 price target on the stock.
• 5/20/2026 – Phreesia had its “equal weight” rating reaffirmed by Wells Fargo & Company. They now have a $9.00 price target on the stock, down from $15.00.
• 5/20/2026 – Phreesia was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $9.00 price target on the stock, down from $15.00.
• 5/14/2026 – Phreesia had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $10.00 price target on the stock, down from $24.00.
• 5/14/2026 – Phreesia was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $10.00 price target on the stock, down from $24.00.
• 4/13/2026 – Phreesia had its price target lowered by KeyCorp from $15.00 to $12.00. They now have an “overweight” rating on the stock.
• 4/4/2026 – Phreesia was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/1/2026 – Phreesia had its “market perform” rating reaffirmed by Citizens Jmp.
• 3/31/2026 – Phreesia had its price target lowered by Stephens from $32.00 to $20.00. They now have an “overweight” rating on the stock.
• 3/31/2026 – Phreesia had its price target lowered by BMO Capital Markets from $32.00 to $14.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Phreesia had its price target lowered by Canaccord Genuity Group Inc. from $33.00 to $22.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Phreesia had its “neutral” rating reaffirmed by JPMorgan Chase & Co.. They now have a $16.00 price target on the stock, down from $24.00.
• 3/31/2026 – Phreesia had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $10.00 price target on the stock, down from $25.00.
• 3/31/2026 – Phreesia had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $11.00 price target on the stock, down from $24.00.
• 3/31/2026 – Phreesia had its “neutral” rating reaffirmed by Robert W. Baird. They now have a $10.00 price target on the stock, down from $25.00.
• 3/31/2026 – Phreesia had its price target lowered by Needham & Company LLC from $35.00 to $14.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In related news, insider David Linetsky sold 8,332 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $8.07, for a total transaction of $67,239.24. Following the transaction, the insider owned 224,056 shares of the company’s stock, valued at $1,808,131.92. This represents a 3.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Allison C. Hoffman sold 14,483 shares of the company’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $8.07, for a total value of $116,877.81. Following the completion of the sale, the general counsel directly owned 163,485 shares in the company, valued at $1,319,323.95. This trade represents a 8.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 50,493 shares of company stock worth $461,983. Insiders own 5.20% of the company’s stock.

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.